2023-06-16
Transcenta to Present Efficacy Data by CLDN18.2 Expression Level from Phase 1/2 Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at 2023 ESMO GI Annual Congress
SUZHOU, China, June 16, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that efficacy data by CLDN18.2 expression level from phase 1/2 study of Osemitamab (TST001) plus Capecitabine and Oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer will be presented as a poster at 2023 ESMO World GI.